Two allogeneic cell therapy switches in a day
Allogene joins Adicet in going back to the drawing board and scrapping trials in late-line aggressive lymphoma.
Astra scoops JP Morgan
Acquiring Gracell at an 86% premium raises hopes that the biotech markets are bottoming out after a turbulent two years.
Another setback for Opdualag's post-melanoma plan
The latest failure, in colorectal cancer, follows a recent disappointment in second-line liver.
ASH 2023 – Regeneron defends its bispecifics
Rates of infection-related deaths continue to raise eyebrows, but the company has some potential explanations.
Crispr abandons first-generation Car-T projects
The company hopes that new edits could solve the relapse problem with allogeneic Car-Ts.
